Kalvista Pharmaceuticals Inc
NASDAQ:KALV

Watchlist Manager
Kalvista Pharmaceuticals Inc Logo
Kalvista Pharmaceuticals Inc
NASDAQ:KALV
Watchlist
Price: 15.46 USD -4.27% Market Closed
Market Cap: 781.5m USD

During the last 3 months Kalvista Pharmaceuticals Inc insiders have not bought any shares, and sold 695k USD worth of shares. The stock price has increased by 41% over this period (open performance analysis).

The last transaction was made on Dec 8, 2025 by Palleiko Benjamin L , who sold 120.4k USD worth of KALV shares.

Last Transactions:
Palleiko Benjamin L
$-120.4k
Yea Christopher
$-58.3k
Audhya Paul K.
$-71.2k
Piekos Brian
$-60.1k
Palleiko Benjamin L
$-147.2k
Sweeny Nicole
$-51.3k
Audhya Paul K.
$-44.5k
Yea Christopher
$-38.8k
Palleiko Benjamin L
$-64.7k
Palleiko Benjamin L
$-38.4k
Palleiko Benjamin L
$-115.5k
Audhya Paul K.
$-31.3k
Yea Christopher
$-26.2k
Sweeny Nicole
$-19.9k
Audhya Paul K.
$-38.9k
Palleiko Benjamin L
$-144.7k
Yea Christopher
$-31.2k
Sweeny Nicole
$-24.6k
Yea Christopher
$-34.9k
Palleiko Benjamin L
$-58.1k
Audhya Paul K.
$-38.8k
Yea Christopher
$-474.7k
Palleiko Benjamin L
$-517.5k
Palleiko Benjamin L
$-104k
Yea Christopher
$-21.8k
Audhya Paul K.
$-24.3k
Palleiko Benjamin L
$-118.7k
Yea Christopher
$-27.5k
Audhya Paul K.
$-31.9k
Audhya Paul K.
$-32.9k
Palleiko Benjamin L
$-45.1k
Yea Christopher
$-30.8k
View All Transactions

During the last 3 months Kalvista Pharmaceuticals Inc insiders have not bought any shares, and sold 695k USD worth of shares. The stock price has increased by 41% over this period (open performance analysis).

The last transaction was made on Dec 8, 2025 by Palleiko Benjamin L , who sold 120.4k USD worth of KALV shares.

Sold
0-3
months
695k USD
5
3-6
months
1.6m USD
4
6-9
months
437k USD
3
9-12
months
229.4k USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
1
235.5k USD
9-12
months
1
3.1m USD

Kalvista Pharmaceuticals Inc
Insider Trading Chart

Kalvista Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Kalvista Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Kalvista Pharmaceuticals Inc
Glance View

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. The company is headquartered in Cambridge, Massachusetts and currently employs 70 full-time employees. The company went IPO on 2015-04-09. The firm is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The firm has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The firm is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. The company has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.

KALV Intrinsic Value
11.48 USD
Overvaluation 26%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top